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DOI 10.1016/j.ccr.2010.12.021SUMMARYSmall cell lung cancer (SCLC) is the lung neoplasia with the poorest prognosis, due to its high metastatic
potential and chemoresistance upon relapse. Using the previously described mouse model for SCLC,
we found that the tumors are often composed of phenotypically different cells with either a neuroendocrine
or a mesenchymal marker profile. These cells had a common origin because they shared specific genomic
aberrations. The transition from neuroendocrine to mesenchymal phenotype could be achieved by the
ectopic expression of oncogenic RasV12. Crosstalk betweenmesenchymal and neuroendocrine cells strongly
influenced their behavior.When engrafted as amixed population, themesenchymal cells endowed the neuro-
endocrine cells with metastatic capacity, illustrating the potential relevance of tumor cell heterogeneity in
dictating tumor properties.INTRODUCTION
Small cell lung cancer (SCLC) accounts for 15%–20% of newly
diagnosed lung malignancies, and is defined by neuroendocrine
differentiation and small cell morphology of the tumor cells.
SCLC is the deadliest and most aggressive type of lung cancer,
mainly due to the early tumor cell dissemination and the almost
invariable recurrence of chemoresistant lesions after chemo-
therapy (Jackman and Johnson, 2005). Tumors initially treated
successfully by chemotherapy recur as chemoresistant variants
and occasionally show progression to a non-SCLC (NSCLC)
phenotype (Abeloff et al., 1979), suggesting the rapid selection
of preexisting chemoresistant cell clones. Tumor cell dissemina-
tion andmetastasis appear to be common, relatively early events
in SCLC. The metastatic capacity could be an intrinsic feature of
neuroendocrine SCLC cells or reflect the specific characteristic
of a rare cell population present in tumors. Unfortunately, studiesSignificance
It is increasingly realized that during tumorigenesis a variety of
tions that are associated with tumor progression. Weinberg an
into the stroma of breast tumors promote metastasis through C
relevance of the interactions between tumor cells and the surro
agreement with this concept but adds an important componen
is generated from a separate subclone during the tumorigenic
new capabilities such as metastatic potential.
244 Cancer Cell 19, 244–256, February 15, 2011 ª2011 Elsevier Inc.with archival patient material have not resolved this, and the
factors critical for metastatic spread during SCLC progression
remain elusive. Research on SCLC has been hampered by
poor access to primary tumor material due to late detection of
tumors, making this tumor inoperable in the vast majority of
cases. In this situation, cell lines are the primary research tool,
although their utility is limited by genetic drift and selection as
a result of serial passaging in vitro with the concomitant loss of
intra-tumor heterogeneity. Furthermore, most human SCLC
cell lines were obtained from metastatic sites or from pleural
effusions (Carney et al., 1985a) and will unlikely retain the cellular
composition of the primary tumor mass.
Intra-tumor heterogeneity with respect to cell morphology but
also proliferation rate, ability to metastasize, sensitivity to drugs,
dependence on growth signals, and tumor initiation/repopula-
tion capacity have since long been recognized as a salient
feature of mostmalignancies. Tumormasses also harbor a rangecells are recruited into the tumor to provide a range of func-
d colleagues showed that mesenchymal stem cells recruited
CL5-mediated paracrine signaling, thereby emphasizing the
unding microenvironment. The work presented here is in full
t: the mesenchymal compartment of the tumor in our system
process, providing the tumor cell population as a whole with
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Cell Heterogeneity in SCLCof normal cell types (stromal and infiltrating cells). The interac-
tions between these different cell types can be critical for tumor
development (Condeelis and Pollard, 2006; de Visser et al.,
2006; Kalluri and Zeisberg, 2006). One particular example of
such interactions was recently reported by Karnoub and collab-
orators (Karnoub et al., 2007): mesenchymal stem cells recruited
into the stroma of breast tumors promote metastasis through
CCL5-mediated paracrine signaling. However, the term ‘‘tumor
heterogeneity’’ is primarily used to denote the diversity observed
in tumor cells themselves, often marked by distinct genetic and
epigenetic alterations (Heppner, 1984). Two current concepts
attempt to explain the variations in cell morphology and behavior
observed in tumors: the cancer stem cell hypothesis, and the
clonal evolution model (Campbell and Polyak, 2007). Although
these two concepts are mutually exclusive when strictly inter-
preted, an intermediatemodel including features of each hypoth-
esis might fit best the actual observations. Mutation and clonal
expansion may generate cells with stem cell properties, being
able to self-renew and differentiate while also accumulating
new mutations that give rise to diverse cell lineages in a tumor.
Although tumor heterogeneity is a recurrent feature of most
tumors, and its origins are now becoming understood, one
important question has remained unanswered: does tumor cell
heterogeneity fulfill a direct functional role, or has it little effect
on tumor properties except for providing a reservoir of variant
cells that permit swift adaptation to altered conditions, such as
exposure to cytotoxic drugs. Work from Heppner’s laboratory
(Heppner, 1993) in the 1970s and 1980s pointed to a very inter-
esting possibility: cell variants in a tumor interact with each other,
resulting in societal behaviors that cannot be predicted by
studying the properties of pure cell populations. However, the
research focus has shifted more toward the identification of
those tumor cells that have the capacity to reconstitute a tumor
(Gangemi et al., 2009; Rosen and Jordan, 2009; Visvader and
Lindeman, 2008). We decided to study to what extent tumor
heterogeneity in SCLCs affects the properties of the tumor cell
population as a whole.
Previously, we have described amousemodel for SCLC (Meu-
wissen et al., 2003) that shows many of the salient features of
human SCLC (Minna et al., 2003). Keeping in mind that ‘‘tumor
heterogeneity is a sort of written history of a particular cancer
from which we can learn’’ (Campbell and Polyak, 2007), we
focused on the identification of cell variants, with the objective
of establishing genotype-phenotype correlations (Calbo et al.,
2005). We now describe their clonal relationship and propose
a model for their generation. Moreover, by conducting in vitro
and in vivo mixing experiments, we address whether the cross-
talk between these variants can alter their properties.
RESULTS
Mouse SCLC Tumors Contain Different
Tumor Cell Populations
To extend the characterization of murine SCLC (Meuwissen
et al., 2003), tumors obtained from 21 mice were dissected,
disaggregated, and cultured in modified HITESmedium (Linnoila
et al., 1993). In all cases, tumor cells expanded rapidly and could
be cultured for extended periods of time. Primary cultures
derived from histology-confirmed SCLC tumors grew as suspen-Csions of small aggregated cells. However, nine of the 21 cultured
tumors also showed cells that attached to the dish. This is
consistent with cell cultures derived from human SCLC tumors
(Carney et al., 1985a).
Given the morphological heterogeneity in the cultured cells,
single-cell suspensions from 15 of the above mentioned cultures
were seeded in soft agar-containingmedium, and individual colo-
nieswere isolatedandexpandedseparately.Most of theobtained
clones grew as suspending aggregates of very small cells. A
similar cellular size and morphology were observed in a small
proportion of adherent cell clones, with cells growing in clusters
or verydensecoloniesandshowingnospreading.However, other
clones grew as a cellularmonolayer composed of larger cells with
visible cytoplasm and spindle-like membrane extensions,
spreadingon thesubstrate.Clonesgrowingassuspendingaggre-
gates were found in all the tumors assayed, whereas 40% of the
same tumors (six out of 15) also gave rise to cloneswith adherent,
large cell phenotype (Figure 1A; see Tables S1 and S2 available
online). Next, we askedwhether SCLC-derived clones expressed
markers of neuroendocrine differentiation. Cells growing as sus-
pending aggregates did express variable amounts of neuroendo-
crine protein markers, as shown in Figure 1B for synaptophysin
(Syp), achaete-scute complex homolog 1 (Ash1), and neural cell
adhesion molecule (NCAM). By contrast, cells with the large cell
phenotype did not show expression of Syp and Ash1, while ex-
pressing relatively low levels of NCAM. Of note, these cells
showed twodiscrete forms (120and180kDa) ofNCAM inwestern
blot, whereas the small cells growing in suspension showed
smeared bands likely related to the characteristic polysialylation
of NCAM protein (Hildebrandt et al., 2008; Lantuejoul et al.,
1998). Six paired cell lines (small cell phenotype/large cell pheno-
type) derived from six independent tumors and three additional
small cell clones were subjected to expression profiling using
oligonucleotide-based microarrays. As controls, one cell line ob-
tained from a histology-confirmed NSCLC and normal lung were
included in the analysis. Principal component analysis (PCA)
showed the clustering of samples into twogroups: one containing
small cell clones from independent SCLC tumors, and another
containing large cell clones from different SCLC tumors. Interest-
ingly, when the three principal components were shown in a 3D
representation (Figure 1C), the large cell cluster was relatively
close to the NSCLC sample, whereas the small cell cluster was
far away, indicating a larger difference in overall expression
profile. A total of 4239 genes were differentially expressed
between small cell and large cell clones. From those the 20
most upregulated and the 20 most downregulated genes were
selected to generate a small cell versus large cell signature (Fig-
ure S1A). The most significant biological functions associated
with the small cell versus large cell upregulated genes, as identi-
fiedby IngenuityPathwaysAnalysis, includedneural-relatedcate-
gories, whereas the ones associated with the downregulated
genes includedcellularmovement, cell-to-cell signaling and inter-
action, and tissue and organismal development (Figure S1B).
Moreover,weobserveddifferential expressionof several neuronal
and neuroendocrine markers (Ascl1 -Ash1-, Elavl4, Syp, Ncam),
which were highly expressed in small cells, and of progenitor
cell and mesenchymal markers (Nestin, Vimentin, Sca1, Bmp4,
Cd44), which were highly expressed in large cells. Interestingly
Mycl1 and Mycn were overexpressed only in small cells. Theancer Cell 19, 244–256, February 15, 2011 ª2011 Elsevier Inc. 245
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Figure 1. Phenotypic Variation in Cell Lines Derived
from Mouse SCLC Tumors
(A) Photomicrographs showing the morphology of cells
growing in suspending aggregates (upper panels) and of
attaching cells featuring spindle-like shape (lower panels).
Cell clones derived from tumors #2 (C2.04 and C2.20), #22
(C22.08 and C22.03), and #896 (C896.04 and C896.02) are
shown. Scale bar, 100 mm.
(B) Western blot analysis of neuroendocrine markers (Syp1,
Ash1, NCAM), L-Myc, mesenchymal markers (Nestin, Vimen-
tin), and GSK3b (loading control) in six clones growing as sus-
pending aggregates (lanes 1–6) and three clones growing as
monolayer (lanes 7–9), derived from six different SCLC tumors
(1:C9.05; 2:C2.04; 3:C18.04; 4:C22.08; 5:C4.06; 6:C788.01;
7:C22.03; 8:C4.05; 9:C788.06).
(C) PCA representing the sample similarities among the
genome-wide expression profiles of nine clones growing as
suspending aggregates (blue) and six clones growing
attached (red); these clones had been derived from eight inde-
pendent SCLC tumors (#2, #4, #9, #18, #22, #610, #788, and
#896; each obtained from a different mouse). Normal lung and
mouse NSCLC cells were used as controls (black).
(D) Photomicrographs showing the morphology (H/E staining)
and immunophenotype of s.c. transplanted tumor cell clones
growing as suspending aggregates (C896.04, upper pictures)
and growing attached (C22.03, lower pictures). Immunohisto-
chemistry was performed using specific antibodies against
NCAM, Ash1, CD44, and Vimentin and developed with DAB
(brown color).
Scale bar, 100 mm. See Tables S1 and S2 for a complete list of
tumors in culture and derived cell lines, and Figure S1 for an
extended expression analysis.
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Cell Heterogeneity in SCLCexpression patterns of Nestin, Vimentin, and L-Myc (Mycl1) were
confirmedbywestern blot (Figure 1B), and the surface expression
of CD44 was confirmed by FACS analysis (Figure 2B).
Several clonal cell lines of each subtype (small, n = 8; large, n =
5) were injected subcutaneously (s.c.) into immunocompromised
Balb/c nu/nu mice. Only cells with the small cell phenotype
generated tumors with SCLC characteristics, whereas cells
with large cell phenotype generated tumors with the large cell
mesenchymal-like marker profile (Figure 1D). Interestingly,
when these transplanted tumors were explanted and cultured
in vitro, they appeared to have fully retained the small or large
cell type features, indicating that neither cell type is capable of
regenerating the heterogeneity seen in the primary tumor (data
not shown). In view of these observations, cell clones with small
cell, neuroendocrine phenotype were named neuroendocrine
(NE) and the ones with large cell phenotype, lacking neuroendo-
crine marker expression, non-neuroendocrine (NonNE).
Presence of NonNE Cells in Primary Mouse SCLC
and in Human SCLC Tumor Cell Lines
Immunohistochemistry performed on primary mouse SCLC
tumors revealed the presence of variable amounts of dispersed246 Cancer Cell 19, 244–256, February 15, 2011 ª2011 Elsevier Inc.CD44 positive cells. Some tumors contained
almost no CD44+ cells, whereas in other tumors
small clusters of CD44+ tumor cells were easily
detected (Figure 2A). Although CD44 expression
is found in various cell types and cannot be used
as a unique marker for NonNE cells, clusteredCD44+ cells in SCLC tumorswere considered transformed tumor
cells because of their cytological characteristics. In support of
this notion, cells with NonNE phenotype could be easily detected
in the first passage of explanted, in vitro cultured tumors with
relatively high CD44+ staining (Figure 2C). Moreover, tumor cell
suspensions containing both NE and NonNE cell populations
could be expanded in vivo by s.c. injection into Balb/c nu/nu
mice, for up to three passages, while retaining both cell popula-
tions (data not shown). In addition we obtained clonal cell lines
from the NCI-H446 human cell line by FACS single CD44+ and
CD44 cells into 96-well plates. Theirmorphologies were consis-
tent with the NonNE (CD44+) and NE (CD44) phenotypes,
respectively (Figure S2).
Clonal Relation of NE and NonNE Cell Lines
Next, we hypothesized that cell clones derived from a single
mouse SCLC tumor might share similarly a common pattern of
genetic aberrations, indicative for their clonal origin. SKY anal-
ysis performed on a NE and a NonNE subline obtained from
a single mouse SCLC tumor was consistent with this hypothesis;
similar translocations were observed in the two lines (Figures 3A;
Figure S3). To confirm these results and obtain higher resolution
AB C
Figure 2. NonNE Cells Are Present in Primary SCLC Tumors
(A) Photomicrographs showing the detection in tumors #675 and #896 of Ash1 and Syp (NE cell markers) and CD44 (NonNE cell marker) by immunohistochem-
istry using specific antibodies and developed with DAB (brown color). Scale bar, 100 mm. Inset in the lower right panel shows a cluster of CD44+ cells.
(B) Flow cytometric analysis of NE cells (C22.08, blue line) and NonNE cells (C22.03, red line) labeled with fluorochrome (PE)-conjugated anti-CD44 monoclonal
antibodies.
(C) Phase-contrast photomicrographs showing cells with divergent morphological characteristics in primary culture of a SCLC tumor (#896, first in vitro passage,
7 days in culture).
See also Figure S2.
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Cell Heterogeneity in SCLCdata, array-CGH analysis was performed using a 1Mb resolution
BAC array platform (Chung et al., 2004). Analyses were carried
out on four pairs of clonal cell lines derived from four different
tumors, and on material of the corresponding primary tumors.
As expected, all cell lines and tumor samples showed copy
number variations, although relatively few genetic aberrations
were observed in each case. The most distinctive changes
were found on chromosome 4. Importantly, cell clones derived
from a single tumor shared some of the genetic aberrations,
characterized by the boundaries of the amplicons, and level of
copy number alteration. For instance, cell clones C22.08 (NE)
and C22.03 (NonNE) derived from tumor #22 showed a common
amplification near the end of chromosome 4, as well as a deleted
area at the very end of chromosome 4. Similarly, cell clones
C788.01 (NE) and C788.06 (NonNE) shared the amplification of
regions on chromosome 4 (Figure 3B). Although these data
confirmed the clonal origin for NE and NonNE cell clones derived
from tumors #22 and #788, respectively, we could not define
shared aberrations in NE and NonNE clones derived from tumor
#4 or #610 using this method. At the same time, marked differ-Cences were also found in all pairs of cell lines. A severalfold
amplification of a narrow region containing the Mycl1 gene was
found only in the cell lines with small cell phenotype, consistent
with the L-Myc protein expression pattern observed by western
blotting (Figure 1B).
RasV12 Induces NE to NonNE Transition
It has been previously described that ectopic expression of
oncogenic mutant HRas protein induces the transition of human
SCLC cell lines to a dedifferentiated phenotype, characterized
by the downregulation of neuroendocrine markers (Falco et al.,
1990; Mabry et al., 1988). Therefore, we investigated whether
Ras activation could drive the transition from NE to the NonNE
phenotype in mouse SCLC clonal cell lines. RasV12 was retrovir-
ally transduced into three NE clonal cell lines derived from inde-
pendent tumors. Although the initial response to oncogenic Ras
expression was a reduction in cell proliferation, all the trans-
duced cultures recovered and showed a transition to an
adherent phenotype, with increased cell size and spreading (Fig-
ure 4A). Ectopic Ras expression also resulted in downregulationancer Cell 19, 244–256, February 15, 2011 ª2011 Elsevier Inc. 247
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Figure 3. Clonal Genetic Alterations in Cell
Variants Obtained from Single Tumors
(A) SKY analysis on the variant cell clones C22.03
NonNE and C22.08 NE obtained from tumor #22
revealed common clonal derivations involving
chromosome 4 (der4/8) and chromosome 8
(der8/2). The results for the complete karyotype
can be found in Figure S3.
(B) DNA from tumor #22 (upper plot, green line)
and its derived cell variants C22.03 NonNE (red
line) and C22.08 NE (blue line), and from tumor
#788 (lower plot, green line) and its derived cell
variants C788.01 NE (blue line) and C788.06
NonNE (red line) were subjected to array CGH
analysis. Log2 signal ratios (tumor versus nontu-
mor genomic DNA) for chromosome 4 are shown
in the figure. In the underlying diagram (OVERLAP),
chromosomal areas showing no copy number
alterations are displayed with a gray bar. Areas
of common DNA copy number changes (NE and
NonNE cell variants) are displayed with black
boxes, representing clonal genetic alterations.
Areas of divergent DNA copy number changes
(NE and NonNE cell variants) are displayed with
yellow-black striped boxes.
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Cell Heterogeneity in SCLCof NE marker expression at the protein level, as shown for Syp
and Ash1 (Figure 4B). Interestingly, a marked downregulation
of L-myc protein expression was observed inRasV12-transduced
cells. Moreover, genome-wide expression profiling showed
profound changes in the transcriptome, and PCA confirmed
a strong similarity between RasV12-transduced NE cells and
NonNE cells, which clustered within the same 3D space and
very well separated from nontransduced and empty vector-
transduced NE cells (Figure 4C). The expression of the genes
included in the NE versus NonNE signature was drastically modi-
fied by RasV12 transduction (Figure 5B). A large fraction of the
genes differentially expressed between NE and RasV12-trans-
duced NE cells overlapped with the set of NE versus NonNE
differentially expressed genes (505/743, Figure 5A). In order to
narrow down the effects of RasV12 expression directly related
to the acquisition of the NonNE phenotype, we identified the
most significant (p < 0.005) overexpressed genes included in
this overlapping gene set (Figure 5C). Thirty genes were identi-
fied, including known mesenchymal markers (Vimentin, CD44)
and several effectors of the Ras-MAPK pathway (c-Myc, Cyclin
D1, Fra-1, RRas, MKP-3). In view of these results, we questioned
whether the MAPK pathway was also activated in NonNE cells
derived from SCLC tumors. Consistent phosphorylation (activa-
tion) of p42/p44 (Erk) was observed in all NonNE cells, but not in
the NE cells tested (Figure S4A). However, sequence analysis of
K-Ras, H-Ras, and N-Ras genes in seven SCLC-derived NonNE
cell lines specifically looking for activating mutations at codon
12, 13, and 61 did not detect any activating mutation (Figure S4;248 Cancer Cell 19, 244–256, February 15, 2011 ª2011 Elsevier Inc.data not shown). Finally, RasV12-trans-
duced cells formed tumors of large,
CD44+, Ash1 cells when injected s.c.
into Balb/c nu/nu mice (Figure 4D) and
were undistinguishable from the tumorsformed by NonNE cells directly isolated from primary SCLC
(Figure 1D).
In Vitro Crosstalk
Next, we wondered whether there is any selection pressure to
maintain cells with these divergent differentiation patterns in
a tumor. To address this question we monitored the effects of
coculturing and cografting both cell types in vitro and in vivo,
respectively, with regard to proliferation and other tumor param-
eters. First, luciferase-labeled NE cells (C896.04) and NonNE
cells (C22.03) were admixed in different ratios to define condi-
tions in which the s.c. grafted mixtures would resemble the
primary tumors with regard to the relative abundances of NE
and NonNE cells. A ratio of four (NE) to one (NonNE) appeared
to give a distribution resembling those of primary tumors with
a relatively high NonNE component. In other studies in which
the contribution of stromal cells to tumor cell behavior was as-
sessed, a one (tumor cells) to three (stromal cells) ratio was
used (Karnoub et al., 2007). We seeded the cells in the 4:1 ratio
in serum-free medium (Figure 6A) and compared to nonmixed
cells. NE cells showed a strong tendency to attach and spread
on the NonNE cell monolayer, while maintaining their small size
(Figure 6B). In fact, mixed cells grew as adherent, multilayered
cultures; this in clear contrast to pure NE cell cultures (floating
aggregates) and to NonNE cells (large cell monolayer). Cells
were counted on days 3, 4, and 5 after seeding. Although both
nonmixed NE and NonNE cultures had limited capacity to
proliferate in serum-free conditions, admixed cells showed
AB C
D
Figure 4. RasV12-Mediated Transition from NE to
NonNE Phenotype
Cell clones with NE phenotype (C2.04, C22.08) derived from
two independent tumors were retrovirally transduced with
the RasV12 gene and analyzed.
(A) Phase-contrast photomicrographs showing the morpho-
logy of RasV12-transduced and empty vector-infected cells.
Scale bar, 100 mm.
(B) Western blot analysis for the detection of neuroendocrine
markers (Syp1, Ash1), mesenchymal markers (Nestin, Vimen-
tin), phospho-Erk1/2, and b-Tubulin (loading control) in NE
cells transduced with the RasV12 gene (+) or with the empty
vector (), as indicated. As controls, nontreated NE and
NonNE cells are shown.
(C) PCA representing the sample similarities among the
genome-wide expression profiles of three NonNE cell clones
(red), two NE cell clones noninfected and empty-vector in-
fected (blue), and the same two NE cell clones transduced
with the RasV12 gene (green).
(D) Photomicrographs showing the morphology (H/E staining)
and immunophenotype of transplanted tumors obtained by
injection of empty vector-infected cells (upper pictures) and
of RasV12-transduced cells (lower pictures) into the s.c. tissue
of immunocompromised mice. Immunohistochemistry was
performed using specific antibodies against NCAM, Ash1,
CD44, and Vimentin and developed with DAB (brown color).
Scale bar, 100 mm.
See also Figure S4.
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Cell Heterogeneity in SCLCa 3- to 4-fold increase in cell number as compared to the sum of
the individually seeded cultures at the time points shown (Fig-
ure 6C). Quantification of luciferase activity, only present in
C896.04 NE cells and not in C22.03 NonNE cells, showed a 4-
fold increment in admixed compared to nonmixed cells after
4 days in culture (Figure 6D), indicating that NE cells have a prolif-
eration advantagewhen cultured in the presence of NonNE cells.
The proportion of NonNE cells in the mixed culture was analyzed
by FACS analysis using CD44 expression as a marker for NonNE
cells (Figure 6E). A 2-fold relative increase in NonNE cell number
in mixed culture compared to nonmixed cells was estimated on
the basis of the percentage of CD44+ and total cell count, sug-
gesting that NonNE cells may also benefit from the presence
of NE cells in the culture, albeit to a lesser extent. The large differ-
ence in CD44 surface expression between NE and NonNE cells
in admixed cultures also permitted purification of the different
cell populations. Using magnetic beads and monoclonal
antibodies against CD44, admixed cells cultured for 4 days
were separated into CD44+ (NonNE) and CD44 (NE) popula-
tions, with over 90% purity (Figure S5). The sorted cells were
morphologically indistinguishable from the parental nonmixed
populations, i.e., admixed, sorted NE cells grew as suspending
aggregates, and NonNE cells as a monolayer.Cancer Cell 19,In an attempt to define the molecular signals
mediating the crosstalk between NE and NonNE
cells, we analyzed secretion of several cytokines
into the culturing medium using an antibody array.
Cells were plated in serum-free medium for
2 days either as single populations or admixed,
andculture supernatantswereanalyzed (FigureS6).
No cytokines were detected in C896.04 NE and inC2.04 NE cell culture supernatants. C22.03 NonNE culture
supernatant contained high levels of several cytokines, including
CCL2 (MCP1), CCL5 (Rantes), CCL9 (MIP-1g), CXCL1 (KC),
CXCL5 (LIX), Selp (P-Selectin), and sTNFR1. Interestingly,
culture supernatants of the admixed cell lines showed de novo
secretion of IGFBP-3 and IGFBP-5. Moreover, the RasV12-medi-
ated phenotypic transition in C2.04 NE cells was accompanied
by the expression of several cytokines, mostly overlapping the
cytokine expression profile observed in C22.03 NonNE cells
(Figure S6).
In Vivo Grafting of NonNE and NE Mixtures
Potentiates Metastasis
Coculturing NE and NonNE cells derived from mouse SCLC had
dramatic effects on cell proliferation and morphology, but the
physiological significance can only be evaluated properly
in vivo. In parallel experiments, luciferase-labeled NE cells
(C896.04) andNonNEcells (C22.03)were injected s.c. into immu-
nocompromised mice either as single populations or admixed at
a 4:1 ratio. Tumor growth was monitored by direct measurement
of tumor diameter with a caliper. In contrast to what we observed
in vitro, growth of admixed cell tumors was not significantly
different from the growth of single tumor cell populations244–256, February 15, 2011 ª2011 Elsevier Inc. 249
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Figure 5. Oncogenic Mutant Ras Induces
Dramatic Changes in Gene Expression
The expression profiles of three NonNE cell clones
(C22.03, C2.20, and C2.21), two NE cell clones
(C22.08 and C2.04), empty-vector infected NE
cell clones (C22.08 p and C2.04 p), and the same
two NE cell clones transduced with the RasV12
gene (C22.08 RasV12 and C2.04 RasV12) were
further analyzed to identify the differentially ex-
pressed genes.
(A) Venn diagram representing the numbers of
differentially expressed genes in each indicated
paired comparison set (p < 0.05), and the overlap
between sets.
(B) Heat map representing the RasV12-induced
variation in the expression of the genes included
in the NE versus NonNE signature, as defined in
Figure S1A.
(C) Heat map representing the expression values
of the genes found overexpressed in both NonNE
versus NE and RasV12 versus NE comparisons
(p < 0.005), corresponding to the highlighted
area in (A).
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Cell Heterogeneity in SCLC(Figure 7A). In fact, NonNE-only tumors showed early engraft-
ment and slow growth, NE-only tumors showed rapid growth
after a lag phase, and mixed-cell tumors showed early engraft-
ment and intermediate growth rate (data not shown). The NE
cell proliferation in single andmixed tumorswas followedby lucif-
erase imaging. Although no reproducible differences were
observed in luciferase signals between these groups (data not
shown), this method yielded an unexpected result. Mice injected
s.c. with mixed populations of cells consistently exhibited
a strong luciferase signal in the upper abdominal region; this in
clear contrast with mice injected with NE cells only, which never250 Cancer Cell 19, 244–256, February 15, 2011 ª2011 Elsevier Inc.showed any luciferase signal in the
abdominal area (Figure 7B).Necropsies re-
vealed the presence of extensive metas-
tases in the liver of mice injected s.c. with
admixed cells (Figure 7C), whereas mice
injected with either NE or NonNE clonal
cell lines showed no evidence for liver
metastases. Careful histopathology and
immunohistochemistry confirmed these
results, i.e., themassive presence ofmeta-
static lesions in the liver of mice injected
s.c. with this combination of NE and
NonNE clonal cell lines and their complete
absence in mice grafted with only a single-
cell population. Immunohistochemistry of
the s.c. admixed tumors showed the pres-
ence of both CD44+; Ash1 and CD44;
Ash1+ cells, distributed in patches. At the
areas of contact between NE and NonNE
populations, CD44+ cells were found inter-
mixed with CD44 cells (Figure 7C),
resembling the distribution observed in
primary mouse SCLC tumors with a rela-tively high fraction of NonNE cells (compare Figure 7C with Fig-
ure 2A). Metastatic lesions were found in the liver and in some
cases in axillary lymphnodes, but not in lungormediastinal lymph
nodes. More importantly, metastatic lesions were constituted of
NE-differentiated cells, with no evidence for the presence of
NonNE cells. This is consistent with the high luciferase signal de-
tected during in vivo imaging of the mice because the luciferase
reporter was only present in the NE cells used in this experiment,
and not in the NonNE cells. To confirm this observation, b-galac-
tosidase-expressing C22.03 NonNE cells were admixed to
C896.04 NE cells and injected s.c. into nude mice. Detection of
AB
C D
E
Figure 6. Increased Proliferation Rate and Morpho-
logical Change in Admixed NE/NonNE Cultures
Luciferase-expressing NE cells (C896.04) and NonNE cells
(C22.03) were used.
(A) Schematic representation of the experimental design. NE-
luc cells were admixed with NonNE cells at a 4:1 ratio, seeded
in serum-free medium, and kept in culture for up to 5 days.
(B) Phase-contrast photomicrographs showing the morpho-
logy of pure NE culture (left), pure NonNE culture (right), and
NE+NonNE mixed culture (middle). Scale bar, 50 mm.
(C) Cell proliferation curves showing the cell counts of pure NE
culture (blue line), pure NonNE culture (red line), and NE+
NonNE mixed culture (orange line). Dotted line represents
the expected cell counts considering the summation of cell
counts in NE and NonNE pure cultures.
(D) Bioluminescence measurement of pure NE cells (blue bar),
pure NonNE cells (red bar), and mixed NE+NonNE cells
(orange bar) after 4 days in culture. Note that only NE cells
express luciferase. (E) Flow cytometric analysis of CD44
expression in pure NE culture (left, in blue), pure NonNE
culture (right, in red), and mixed NE+NonNE culture (middle,
in orange), 4 days after seeding. The quantification of CD44+
cell (percentage) is shown.
Data are represented as mean ± SD. See also Figure S5.
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Cell Heterogeneity in SCLCb-galactosidase expression by immunohistochemistry showed
clustered and interspersed C22.03 NonNE cells in the grafted
tumors, but not in the livermetastasis, nor in the liver parenchyma
(Figure 7D). The enhanced potential to metastasize was found to
be a reproducible phenotype because it could be reproduced in
three independent graft experiments, with an overall incidence of
liver metastases of 17/18 mice injected with the admixed cell
populations. In contrast, none of the six mice injected with
C896.04 NE cells alone and of the six mice injected with C22.03
NonNE cells alone presented with liver metastases (Figure 7E).
Combinations involving these and other cell lines (C2.20 NonNE,
C788.06 NonNE, C610.01 NE, C2.04 NE) were also tested in the
same system. Four of the combinations (C22.03/C896.04,
C22.03/C2.04, C2.20/C896.04, and C2.20/C2.04) had a statisti-Cancer Cell 19,cally significant increase in metastatic incidence
(p < 0.05), when comparing NE cells injected alone
or in combination with NonNE cells. The fact that
some combinations gave a higher metastasis rate
than others is likely due to different in vivo prolifera-
tion rates of each of the cell lines tested, changing
the ratio between NE and NonNE cells in the tumor.
The incidence of livermetastasis over all the combi-
nations and experiments was 35 out of 53 mice,
whereas none of 30 mice injected with single-cell
populations showed distant spreading of tumor
cells (p < 0.05). Altogether, these results indicate
that the presence of NonNE cells in s.c. grafted
tumors endows the NE cells with a dramatically
enhanced ability to metastasize to the liver.
Next, we questioned whether enhanced meta-
static potential was a systemic effect or required
close contact between different cell populations.
C896.04 NE cells were injected s.c. into the left
and C22.03 NonNE into the right flank of thesame immunocompromised animals. None of the seven animals
injected with this combination of cells at contralateral flanks
developed liver metastases, suggesting that close contact or
vicinity of both cell populations within the same tumor is required
to confer the metastatic potential to the NE cell population.
DISCUSSION
Mouse SCLC tumors share many features with human SCLC,
including cellular morphology, marker profile, and pattern of
metastatic spread to specific organs. Here, we show that mouse
SCLC tumors are often composed of multiple tumor cell types:
small NE cells and large NonNE cells withmesenchymal features.
The derivation of cell lines with different cell morphologies from244–256, February 15, 2011 ª2011 Elsevier Inc. 251
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C Figure 7. Enhanced Metastatic Potential of
NE Cells When Admixed to NonNE Cells in
Graft Experiments
(A) Tumor volume measurement of transplanted
tumors after injection of pure NE cells (C896.04,
blue line), pure NonNE cells (C22.03, red line), or
mixed NE+NonNE cells (orange line). Data are
presented as mean ± SD; asterisks denote
a volume difference between pure NE and pure
NonNE tumors (p < 0.05).
(B) In vivo detection of luciferase reporter expres-
sion by bioluminescence imaging. NE cells
(C896.04) were the only cells expressing lucif-
erase. In this picture, two mice injected into both
flankswith pure NE cells (blue line, left), onemouse
injected into both flanks with pure NonNE cells
(red line, right), and two mice injected with mixed
NE+NonNE cells (orange line, middle) are shown.
(C) Upper panels show the morphology (H/E stain-
ing, left) and the expression of Ash1 (middle) and
CD44 (right) by immunochemistry (DAB, brown
color) of a subcutaneously transplanted tumor
after injection of NE+NonNE mixed cells. Scale
bars, 100 mm. Lower panels show the extensive
metastatic colonization of the liver in mice injected
s.c. with mixed NE+NonNE cells.
(D) Detection of b-gal expressing C22.03 cells
(NonNE) by immunohistochemistry (DAB, brown
color) in the subcutaneously transplanted tumors
and metastases (two upper and two lower-right
photomicrographs, respectively) after injection of
mixed NE+NonNE cells. In the same mouse, liver
metastases were stained positive for NCAM (lower
left). Scale bars, 100 mm (low magnification) and
20 mm (high magnification).
(E) Frequency of metastases in Balb/c Nude mice
injected with either pure NE cells, pure NonNE
cells, or the NE+NonNE mix, as indicated. The
frequency is expressed as number of mice with
liver metastases/number of mice in that group.
# indicates the detection of lymph node metas-
tasis in mice lacking liver metastases. Asterisks
denote statistical significance (chi-square test)
with p < 0.05. See also Figure S6.
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Cell Heterogeneity in SCLChumanSCLC tumors has alsobeen reported (Carneyet al., 1985a,
1985b).However, theprocedures for deriving thesecell linesmight
have limited the persistence of heterogeneous cultures to rare
cases, either because culture conditions selected for specific vari-
ants or because cell lines were derived from metastatic locations
that exclusively were composed of tumor cells with neuroendo-
crine characteristics. Interestingly, the NCI-H446 SCLC human
cell line can be propagated as amixture of adherent and suspend-
ing cells, and these populations can be separated based on differ-
ential adherence to substrate (Doyle et al., 1990). It is important to
pointout that thephenotypicallydifferentcell variants isolated from
individualmurine (this work) and human tumors (Doyle et al., 1990;
Watanabe et al., 1988) are often of clonal origin but show signifi-
cant differences at the genetic level. Our results using SCLC cell
lines are in agreement with those of Watanabe and collaborators
(Watanabe et al., 1988), who reported that several chromosomal
markers were shared by the different human SCLC sublines,
whereasMYCL1amplificationwasonlypresent in the twosublines
expressing neuroendocrine antigens. This conforms to the notion
that in general, tumors originate from a single cell that undergoes252 Cancer Cell 19, 244–256, February 15, 2011 ª2011 Elsevier Inc.a repetitive process of mutation, selection, and expansion (Fig-
ure 8). During this process new cell variants arise, and some of
them, most likely ‘‘the fittest,’’ will expand, whereas others are
lost. However, variant clones with similar fitness but with proper-
ties for which no selection is imposed will persist and contribute
to the genetic diversity of the tumor. From the viewpoint of popu-
lation genetics, genetic variability is an advantageous feature
because it better permits adaptation to changes in the environ-
ment. Tumor heterogeneity easily results fromchromosomal insta-
bilityorDNArepairdefects,whicharehallmarksof tumorcells.This
might alsopermit the concomitant selectionwithin the same tumor
of cell clones that coevolve with mutual dependencies, giving rise
to a tumor tissue in which the different tumor cell clones fulfill their
own specific function. The recurrent presence, in independent
tumors, of neuroendocrine and NonNE tumor cell clones is
a remarkable demonstration of such coevolution process. We
speculated that the coexistence of NE and NonNE cells in a tumor
confers a selective advantage to the tumor as a whole.
We show here that within largely neuroendocrine SCLC
tumors, variant tumor cell clones can be found that lack
p53 & Rb loss 
other mutations 
Normal lung 
NE cells
Mycl1 amplification Tumor 
NE cells 
Tumor 
NonNE cells 
CROSS-TALK 
A SCLC tumorB
Ras-pathway activation 
Mycl1 downregulation 
Figure 8. Generation of Functional Cell Heterogeneity in SCLC
Tumors
The model describes the sequence of events that might create cell heteroge-
neity with a functional role in SCLC tumors, in line with our observations.
(A) Tumor cell progression is driven by a repeated cycle of mutation, cell
expansion, and natural selection. In the mouse SCLC tumor model used
here, Trp53 and Rb1 deletions initiate the tumorigenic process. Genetic insta-
bility is the driving force facilitating accumulation of new mutations and gener-
ating genetic variability within the tumor mass. Mycl1 amplification might be
a relevant progression step for NE cells in SCLC tumor because this is the
most common spontaneous genetic alteration observed in mouse SCLC
tumors. NonNE variants may originate from NE tumor cells upon activation
of the Ras-signaling pathway. Oncogenic Ras expression in NE cells may
block the expression of L-myc. The genetic variants present in a tumor are
under continuous evolutionary pressures resulting in the selection of the fittest
variants. This includes advantageous properties conferred by paracrine
signaling leading to coevolutionary selection of subclones.
(B) As a consequence of the processes described in (A), SCLC tumors are
composed of highly progressed NE cells (dark blue), and other variant cell line-
ages, representing less progressed NE cells (light blue) or NonNE cells (red).
The tumor as a whole has a neuroendocrine phenotype (‘‘looks blue’’) but
harbors cell variants that convey specific tumor features.
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Cell Heterogeneity in SCLCneuroendocrine differentiation and express mesenchymal
markers. As mentioned before, similar NonNE cell variants were
previously described in a few human SCLC cell lines (Doyle
et al., 1990; Watanabe et al., 1988), but neither of these reports
questioned how these variants were generated nor did they
address the possible consequences for the SCLC tumor. Other
groups studied oncogenic-Ras-induced dedifferentiation of
human SCLC cell lines and interpreted it as a progression event
related to the occasional transition from a SCLC to a NSCLC
phenotype in relapsed tumors. Our experiments indicate that
expression of oncogenic Ras in mouse SCLC cell lines with
a NE phenotype is sufficient to cause the transition to the NonNE
phenotype. Ras-transduced cells silence the expression of NE
markers and upregulate the expression of Vimentin and CD44,
thereby imposing a NE tomesenchymal transition. Because intro-
duction of mutant Ras into L-myc expressing NE cells resulted in
cells inwhichL-mycexpressionwas lost, theNonNEcells as found
in the primary tumors could arise from preexisting NE cells that
either did or did not carry a Mycl1 amplification (Figure 8).
Our results suggest that spontaneous transition to the NonNECphenotype requires activation of the MAPK pathway, although
no Ras-activating mutations have been found in NonNE cell lines.
Identification of the mutations that activate the MAPK pathway in
the specific genetic context of neuroendocrine tumor cells will be
addressed in future work. Furthermore, we cannot exclude the
possibility that NE cells have arisen from progenitor cells with
NonNE features, by the expression of factors, such as Ascl1,
promoting neuroendocrine differentiation. Ascl1 has recently
been shown to collaborate with other factors in the conversion of
fibroblasts into neurons (Vierbuchen et al., 2010). Whatever the
precise route,wequalify this tumorcelldiversificationasaprogres-
sion step that confers new malignant capacities to the tumor.
By setting up in vitro and in vivo mixing experiments, we
observed synergistic effects on in vitro proliferation. In vivo, an
unexpected enhancement of the metastatic potential of the NE
cells was observed. The apparent discrepancy between the
in vitro and in vivo proliferation capacity points to the existence
of a limiting factor in the culture medium that becomes irrelevant
in the context of grafted cells. Nonetheless, both systems illumi-
nate the crosstalk between these tumor cell variants. EMT transi-
tions have been described in detail in development, where they
contribute to the plasticity required for the (re-)organization of
tissues. They can fulfill a similar role in tumor progression by facil-
itating tumor cell invasion andmetastasis (Polyak andWeinberg,
2009). In carcinomas, mesenchymal transitions can originate
from microenvironmental signals or from (epi-)genetic changes.
However, the precise mechanisms by which tumor cells with
mesenchymal traits contribute to the consecutive steps resulting
in colonization of distant organs by tumor cells are still largely
unknown. The fact that most (if not all) metastases from epithelial
carcinomas show epithelial differentiation at the metastatic site
seems at odds with the observation that carcinomas that
undergo EMT have an enhanced metastatic capacity. Two
possible explanations have been proposed (Polyak and Wein-
berg, 2009). Tumor cells that underwent EMT in theprimary tumor
disseminate and seed distant organs where they undergo
a mesenchymal to epithelial transition (MET), thereby regaining
epithelial features. Alternatively, there could be a functional
cooperation between mesenchymal and epithelial cells that
potentiates the epithelial cells to metastasize, e.g., by the forma-
tion of mixed cell clumps that together better survive in the circu-
lation (Hart, 2009) and/or by direct signaling (Lyons et al., 2008).
Considering that theNE toNonNE transition in neuroendocrine
SCLC tumors parallels the EMT processes described for epithe-
lial carcinomas, our results conform to the latter mechanism.
Indeed, NonNE cells in the tumor grafts enhance the capacity
of NE cells to metastasize, whereas NonNE cells do not metas-
tasize in either mixed or nonmixed tumors. A similar case of cell
cooperativity in metastasis involving EMT transition on hamster
cheek pouch carcinoma-1 cells (HCPC-1) has been recently re-
ported (Tsuji et al., 2008, 2009). Our results also indicate that
neuroendocrine to mesenchymal transition in SCLC is a rare
event that requires profound (genetic) changes that are not easily
reverted because: (1) in all cases tested, NE and NonNE clones
from a particular SCLC tumor present with marked differences in
their CGH profile; (2) cloned NE and NonNE cell lines maintain
their phenotype over a large number of passages in culture;
and (3) forced transition from NE to NonNE phenotype was
accomplished by overexpressing mutated RasV12 protein andancer Cell 19, 244–256, February 15, 2011 ª2011 Elsevier Inc. 253
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Cell Heterogeneity in SCLCafter recovery of the cells from the initial RasV12-induced crisis.
These data outline a scenario in which tumor cells converted to
a mesenchymal phenotype by mutation and selection, create
together with the NE cells a tumor microenvironment that is
advantageous for both cell types, thereby securing their reten-
tion in the tumor. Evidently, increased metastatic potential
cannot be by itself the driving force commanding retention or
expansion of NonNE cells in SCLC tumors and, thereby, hetero-
geneity. However, mesenchymally differentiated tumor cells
could participate in the reorganization of the tumor tissue as
it has been described for EMT-affected cells in carcinomas, in
several different ways: increasing motility and invasiveness,
offering survival signals to other tumor cells, producing extra-
cellular matrix and proteases, inducing inflammation, and
promoting vascularization. Increased metastatic potential could
be a by-product of one or several of these changes. It has been
reported that mesenchymal stem cells enhance the metastatic
potential of breast cancer cells at least in part by expressing
the chemokine CCL5 (also known as Rantes). We have studied
the expression of several chemokines in NE, NonNE, and mixed
populations in vitro. Interestingly, CCL5 is expressed by NonNE
cells whether or not they are admixed to NE cells. Still, several
other cytokines are constitutively expressed by NonNE cells.
Some of those are known to be proinflammatory and/or to
contribute to the metastatic process in other systems.
In summary, our work presented here describes a specific
type of tumor heterogeneity, in which the interaction between
clonally derived but diversified subclones alters the behavior of
the tumor as a whole. One of the outcomes is a substantially
increased metastatic potential, a feature with important clinical
ramifications. It makes us aware of the fact that tumor heteroge-
neity can have profound functional consequences. Tumor cell
behavior then not only depends on the interactions with stromal
cells but is also influenced by interactionswith tumor cell variants
that fulfill a distinct role in the tumor tissue. Enhanced metastatic
capacity serves as an illustrative example of crosstalk between
specialized tumor cell clones. Disrupting the paracrine signaling
involved in this interaction is worth further exploring as a strategy
to mitigate tumor progression.
EXPERIMENTAL PROCEDURES
A detailed description of the materials andmethods utilized in this work can be
found in the available online Supplemental Experimental Procedures.
Mouse Model for SCLC
All experiments involving animals comply with local and international
regulations and ethical guidelines, and have been authorized by our local
experimental animal committee at The Netherlands Cancer Institute
(DEC-NKI). We have used the mouse model for SCLC described previously
(Meuwissen et al., 2003). Compound Trp53F2-10/ F2-10;Rb1F19/F19 and
Trp53F2-10/ F2-10;Rb1F19/F19;LucR (Kazarian et al., 2009) were induced by intra-
tracheal delivery of 108 Ad5-CMV-Cre viral particles. When moribund, mice
were sacrificed by CO2; tumors were excised and processed for further
analysis.
Derivation of Cell Lines and RasV12 Transduction
Excised tumors were mechanically disaggregated with a sterile blade, cleared
from large aggregates, washed with PBS, and seeded in modified HITES
medium. To split cell cultures, suspending aggregates were harvested and
mechanically disaggregated by pipetting up and down with a p200 micropi-254 Cancer Cell 19, 244–256, February 15, 2011 ª2011 Elsevier Inc.pette. Adherent cultures were washed (PBS) and detached by incubating the
cells in Trypsin (Invitrogen) for 5min at room temperature. Clonal cell lines were
derived from these cultures by preparing single-cell suspensions, passing
them through a 40 mm sieve, and seeding them at different densities in soft-
agar plates. RasV12 transduction was performed using pBABE-puro-RasV12
retroviruses with empty vector pBABE-puro retroviruses as control (Peeper
et al., 2001), followed by a 72-hr selection in medium containing puromycin
(Sigma).
WB Analysis
Protein separation and immunodetection (western blot) was performed as
previously described with minimal changes (Calbo et al., 2002). We used the
following primary antibodies against: Syp (rabbit polyclonal; Dako); Ash1
(mouse monoclonal; BD Biosciences); L-Myc (H-44, rabbit polyclonal; Santa
Cruz); NCAM (Rabbit polyclonal; Chemicon); Nestin (mouse monoclonal; BD
Biosciences), Vimentin (mouse monoclonal; BD Biosciences); and p-Erk
(rabbit monoclonal; Cell Signaling). GSK-3b (rabbit polyclonal; Santa Cruz)
and b-tubulin (mouse monoclonal; Klinipath) served as loading controls.
Histology and Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were cut into 4 mm sections and
deposited on glass slides. For histological analysis, tissue sections were
stained with hematoxylin and eosin (H/E). For immunohistochemistry, tissues
were rehydrated, blocked in BSA containing PBS, and sequentially incubated
with specific primary antibodies and with biotinylated secondary antibodies.
For visualization we used streptABComplex (Dako) and diaminobenzidine
(Dako) as a chromogen, following the instructions of the provider. Hematoxylin
was used as a counterstain. The following antibodies were used against:
NCAM (Rabbit polyclonal; Chemicon); Ash1 (mouse monoclonal; BD Biosci-
ences); CD44 (rat monoclonal clone IM7; Santa Cruz); Vimentin (guinea pig
polyclonal; RDI Fitzgerald Industries); Syp (mouse monoclonal clone SY38;
Dako); and b-gal (rabbit monoclonal; Invitrogen). Biotinylated GoataRab,
GoataMouse, RabbitaRat (all from Dako), and GoataGuinea pig (Jackson
Laboratories) were used as secondary antibodies.
CGH Analysis
DNA was either isolated as described previously (Jongsma et al., 2008)
or using a Puregene DNA isolation kit following the manufacturer’s instruc-
tions. All hybridizations were performed as previously described (Shakhova
et al., 2006). For mouse genome information we used the Ensembl mouse
genome server (v46, August 2007) based on the National Center for Biotech-
nology Information m36 mouse assembly (freeze May 08, 2006, strain
C57BL/6J).
SKY Analysis
Metaphase preparations were hybridized using the mouse SkyPaint probe
mixture (Applied Spectral Imaging, Migdal Ha’Emek, Israel) according to the
manufacturer’s instructions and mounted in 40,6-diamidino-2-phenylindole/
antifade solution. Using the SpectraCube 200 system and the skyview analysis
software (Applied Spectral Imaging), eight to ten metaphases from each
mSCLC clonal cell line were examined.
Expression Analysis and PCA
A 32K mouse oligoarray (Operon Biotechnologies, Inc.) was used for the
relative quantification of mRNA expression profile, taking the Universal
Mouse reference RNA (Stratagene) as reference. Results were then sub-
jected to PCA from experiments using the Genesis Software (Institute for
Genomics and Bioinformatics, Graz University of Technology, Graz, Austria
[IGB-TUG]).
Transplantation of Cell Lines
Balb/c Nude immunosuppressed mice were used for s.c. transplantation
of tumor cell lines. Injections of cells were performed in both flanks. Cell
lines were injected as single-cell suspensions either as pure populations
(NE 53 105 cells, NonNE 13 105) or mixed at a ratio 4:1 (NE 43 105 + NonNE
13 105 cells). Subcutaneously injected Balb/c nude mice were imaged on the
IVIS200 (CCD camera; Biocompare) once a week. Tumors were allowed to
Cancer Cell
Cell Heterogeneity in SCLCgrow until a maximum volume of 1500 mm3, and then mice where euthanized
and tumors processed for further analysis.ACCESSION NUMBERS
CGH array and expression array data have been deposited in the public data-
base ArrayExpress (E-NCMF-36 and E-NCMF-37, respectively).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at doi:10.
1016/j.ccr.2010.12.021.
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